Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 4 Neoplasms 2 Kidney Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Pleural Neoplasms 1 Pleural Effusion, Malignant 1 Pleural Effusion 1 Pleural Diseases 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Lung Neoplasms 1 Lung Diseases 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Gastro Intestinal Stromal Tumor 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Bronchogenic 1

Interventions

Paclitaxel 96 Carboplatin 81 Bevacizumab 62 Gemcitabine 36 liposomal doxorubicin 32 pembrolizumab 30 Topotecan 26 olaparib 23 Taxes 23 niraparib 17 Immunoglobulin G 17 Disulfides 17 Docetaxel 16 Cyclophosphamide 16 Cisplatin 14 Nivolumab 11 rucaparib 10 durvalumab 10 Doxorubicin 9 Albumin-Bound Paclitaxel 8 sargramostim 7 pazopanib 7 fludarabine phosphate 7 fludarabine 7 avelumab 7 Magnetic Resonance Spectroscopy 7 Ifosfamide 7 epacadostat 6 Trabectedin 6 Sorafenib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Ovarian Neoplasms × Tyrosine Kinase Inhibitors × Clear all

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡